Versor Investments LP Raises Stock Position in Integer Holdings Co. (NYSE:ITGR)

Versor Investments LP boosted its position in shares of Integer Holdings Co. (NYSE:ITGR) by 48.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,404 shares of the medical equipment provider’s stock after acquiring an additional 1,104 shares during the period. Versor Investments LP’s holdings in Integer were worth $443,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Blue Trust Inc. increased its stake in Integer by 460.4% in the second quarter. Blue Trust Inc. now owns 5,643 shares of the medical equipment provider’s stock valued at $658,000 after acquiring an additional 4,636 shares during the last quarter. UniSuper Management Pty Ltd bought a new position in Integer in the first quarter valued at $976,000. Earnest Partners LLC increased its stake in Integer by 3.2% in the second quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock valued at $139,911,000 after acquiring an additional 37,340 shares during the last quarter. Great Lakes Advisors LLC increased its stake in Integer by 56.7% in the second quarter. Great Lakes Advisors LLC now owns 45,218 shares of the medical equipment provider’s stock valued at $5,236,000 after acquiring an additional 16,355 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Integer in the third quarter valued at $651,000. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Analyst Ratings Changes

ITGR has been the topic of a number of research analyst reports. Benchmark increased their target price on Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Truist Financial reduced their target price on Integer from $150.00 to $147.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. KeyCorp raised their price objective on Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Piper Sandler reaffirmed an “overweight” rating and set a $140.00 price objective (up from $125.00) on shares of Integer in a research note on Friday, October 25th. Finally, Bank of America raised their price objective on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $139.75.

Integer Stock Performance

Shares of ITGR opened at $134.91 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. Integer Holdings Co. has a one year low of $84.75 and a one year high of $140.91. The company has a 50-day simple moving average of $129.02 and a two-hundred day simple moving average of $122.37. The firm has a market capitalization of $4.52 billion, a PE ratio of 41.64, a price-to-earnings-growth ratio of 1.97 and a beta of 1.09.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. Integer had a net margin of 6.70% and a return on equity of 11.63%. The business had revenue of $431.42 million during the quarter, compared to the consensus estimate of $440.59 million. During the same quarter last year, the firm earned $1.27 earnings per share. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, analysts anticipate that Integer Holdings Co. will post 5.33 EPS for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.